Paul August | Chief Scientific Officer
ReviR Therapeutics

Dr. Paul August has dedicated his career to transforming scientific discovery into tangible hope for patients battling rare and neurological diseases.  Dr. August currently serves as Chief Scientific Officer at ReviR Therapeutics, where he spearheads innovative research programs for devastating neurological disorders. His scientific journey includes nearly two decades at Sanofi as a executive leader, followed by leadership roles as a Vice President at Agios and Icagen Pharmaceuticals. Dr. August co-founded AcuraStem and advanced AS-02 for ALS, a program Takeda acquired in 2023. His body of work encompasses more than 30 peer-reviewed publications, 10 patents, and over $30 million in competitive research funding, including a recent $4.6 million grant from the California Institute of Regenerative Medicine to advance a breakthrough therapy for Huntington's disease. Whether developing life-saving therapies, mentoring emerging biotech entrepreneurs, or strengthening regional innovation networks, Dr. August remains focused on ensuring that groundbreaking science reaches the patients who need it most.